

## Santen Announces Share Buyback

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter, Santen) announced that its Board of Directors resolved today to repurchase its own shares in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

### 1. Reasons for Repurchase of Own Shares

This repurchase is implemented in accordance with the capital allocation policy in the new medium-term management plan (FY2023-2025) dated on April 13, 2023, to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment.

### 2. Details of Repurchase

(1) Class of shares to be repurchased	Common shares
(2) Total number of shares to be repurchased	18,750,000 shares (maximum) *Representing 5.0% of the total number of shares outstanding (excluding treasury shares)
(3) Total amount of repurchase	24.5 billion yen (maximum)
(4) Period of repurchase	May 12, 2023 to March 22, 2024
(5) Method of repurchase	Open-market repurchase by the discretionary trading method

Santen plans to cancel the repurchased shares by its Board of Directors resolution in accordance with Article 178 of the Companies Act (Japan).

There is a possibility that some of the purchases may not be made depending on investment opportunities or market conditions.

(Reference) Treasury Shares Information as of March 31, 2023

Total number of shares outstanding (excluding treasury shares)	375,582,698 shares
Treasury shares	303,156 shares

**Contact:**

Guillaume Sakuma  
Global Head of IR, IR Group  
E-mail: [ir@santen.com](mailto:ir@santen.com)

**About Santen**

As a specialized company dedicated to eye health, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries and regions.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, Santen aims to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en>).